Treating to target of minimal disease activity and normal function in polyarticular juvenile idiopathic arthritis with adalimumab: analysis from a phase 3 clinical trial

Παρόμοια τεκμήρια

• Administration of routine preventative vaccinations in children with polyarticular juvenile idiopathic arthritis receiving adalimumab
  ανά: Minden, Kirsten, κ.ά.
  Έκδοση: (2014)
• Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven‐Year Interim Results
  ανά: Brunner, Hermine I., κ.ά.
  Έκδοση: (2020)
• Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years
  ανά: Kingsbury, Daniel J., κ.ά.
  Έκδοση: (2014)
• 7.4 Improvements in individual disease components are sustained with long-term adalimumab therapy for polyarticular Juvenile Idiopathic Arthritis
  ανά: Ruperto, N, κ.ά.
  Έκδοση: (2008)
• Oral or Parenteral Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
  ανά: Reima Bakry, κ.ά.
  Έκδοση: (2022-10-01)